RecruitingPhase 4NCT07249788
Resmiterom Efficacy & Safety in Patients With MASH
Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study
Sponsor
Nabiqasim Industries (Pvt) Ltd
Enrollment
165 participants
Start Date
Oct 17, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria6
- At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)
- Clinical diagnosis of MASH using:
- LSM ≥ 8.5kpa And/or
- FAST score ≥0.67 And/or
- FibroScan CAP ≥ 275 dB/m And/or
- FIB-4 > 1.3
Exclusion Criteria9
- History of drug addiction and alcoholism
- Cirrhosis or decompensated liver disease
- Chronic viral hepatitis HBV, HCV)
- MACE including MI, Stroke, PE etc.
- Pregnant/lactating women
- Concurrent use of other investigational drugs
- History of other liver diseases (viral, autoimmune, drug-induced, alcohol)
- Previous use of resmetirom in last 6 months
- Significant renal impairment (eGFR <30)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGResmetirom
1st FDA approved MASH therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07249788
Related Trials
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314323 locations
Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer
NCT068249741 location
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT0733560117 locations
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
NCT0763267722 locations
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
NCT0730380317 locations